The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the randomized phase III SUCCESS-A study.
Wolfgang Janni
Consultant or Advisory Role - Lilly; Novartis; Sanofi
Honoraria - Lilly; Sanofi
Research Funding - AstraZeneca; Chugai Pharma; Lilly; Novartis; Pfizer; Sanofi
Andreas Schneeweiss
Consultant or Advisory Role - Celgene; Roche
Honoraria - Celgene; Roche
Lothar Haeberle
No relevant relationships to disclose
Peter A. Fasching
Consultant or Advisory Role - Genomic Health; Novartis; Roche
Honoraria - Genomic Health; Novartis; Roche
Research Funding - Amgen; Novartis
Harald Leo Sommer
No relevant relationships to disclose
Mahdi Rezai
No relevant relationships to disclose
Joern Hilfrich
No relevant relationships to disclose
Hans Tesch
No relevant relationships to disclose
Georg Heinrich
No relevant relationships to disclose
Helmut Forstbauer
No relevant relationships to disclose
Thomas W. P. Friedl
No relevant relationships to disclose
Fabienne Schochter
No relevant relationships to disclose
Susanne Albrecht
No relevant relationships to disclose
Bernadette Jaeger
No relevant relationships to disclose
Julia Kathrin Jueckstock
No relevant relationships to disclose
Klaus Friese
No relevant relationships to disclose
Werner Lichtenegger
No relevant relationships to disclose
Matthias W. Beckmann
No relevant relationships to disclose
Brigitte Kathrin Rack
Consultant or Advisory Role - AstraZeneca; Chugai Pharma; Lilly; Novartis; Pfizer; Sanofi